



(51) International Patent Classification:

C07D 239/96 (2006.01) *A61P 9/00* (2006.01)
C07D 401/06 (2006.01) *A61P 35/00* (2006.01)
A61K 31/517 (2006.01)

(21) International Application Number:

PCT/CN2012/073362

(22) International Filing Date:

31 March 2012 (31.03.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201110082475.6 1 April 2011 (01.04.2011) CN
 PCT/CN2011/077034 11 July 2011 (11.07.2011) CN

(71) Applicant (for all designated States except US): **IMPACT THERAPEUTICS, INC.** [CN/CN]; 10 Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CAI, Sui Xiong** [US/CN]; 10 Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN). **TIAN, Ye Edward** [US/CN]; 10 Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN). **DONG, Haijun** [CN/CN]; 1357 Huqingping Road, House 261, Shanghai 201702 (CN). **XU, Qingbing** [CN/CN]; 10 Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN). **WU, Lizhen** [CN/CN]; 10 Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN). **LIU, Lijun** [CN/CN]; 10 Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN). **JIANG, Yangzhen** [CN/CN]; 10 Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN). **BAO, Qingli** [CN/CN]; 10

Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN). **WANG, Guoxiang** [CN/CN]; 10 Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN). **YIN, Feng** [CN/CN]; 10 Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN). **GU, Chengyun** [CN/CN]; 10 Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN). **HU, Xiuhua** [CN/CN]; 10 Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN). **WANG, Xiaozhu** [CN/CN]; 10 Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN). **KANG, Sishun** [CN/CN]; 10 Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN). **CHEN, Shengzhi** [CN/CN]; 10 Xinghuo Road, Floor 9, Nanjing, Jiangsu 210061 (CN).


(74) Agent: **SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC**; 435 Guiping Road, Shanghai 200233 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]

(54) Title: 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES AS PARP INHIBITORS AND THE USE THEREOF



(57) Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones thereof, represented by the Formula (I) wherein Ar, R₁-R₆ are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.



LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, **Published:**

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — *with international search report (Art. 21(3))*
GW, ML, MR, NE, SN, TD, TG).